Back to search

Article

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china.

2021-01-08

Abstract excerpt

<h4>Background: </h4> Breast cancer is the most common cancer among women in China. Amplification of the Human epidermal growth factor receptor type 2 (HER2) gene is present and overexpressed in 18–20% of breast cancers and historically has been associated with inferior disease-related outcomes. There has been increasing interest in de-escalation of therapy for low-risk disease. This study analyzes the cost-effect...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8c8507ae-b2e7-5b54-bb18-53f2ae0d0d8b
DOI
10.21203/rs.3.rs-31972/v3
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china.DOI 10.21203/rs.3.rs-31972/v3
Cost-effectiveness of Trastuzumab emtansine and Capecitabine plus lapatinib in adjuvant treatment of Human Epidermal Growth Factor Receptor 2– Positive Metastatic Breast Cancer in ChinaSemantic proximity
Cost-Effectiveness Analysis of talazoparib Maintenance Treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the USSemantic proximity
Cost-Effectiveness of Sacituzumab Tirumotecan vs Chemotherapy for EGFR- TKI–Resistant NSCLC: Evidence to Inform Drug Pricing in the U.S. and ChinaSemantic proximity
Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer.Semantic proximity
The relationship between hormone receptor status, tumor size and clinical stage and the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer, predictors of survival, and the establishment of Cox-Based risk prediction model and nomogramSemantic proximity
Cost-utility analysis of genomic profiling in early breast cancer in ColombiaSemantic proximity
Trastuzumab in combination with capecitabine plus cisplatin for the treatment of advanced HER2-positive gastric cancer: A systematic review and meta-analysisSemantic proximity
The precise chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus the classic chemotherapy in the treatment of breast cancer: a comparative effectiveness researchSemantic proximity
Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In ChinaSemantic proximity
A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancerSemantic proximity
Omission of Chemotherapy in HR+/HER2- Early Invasive Breast Cancer Based on Combined 6-IHC Score?Semantic proximity
Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.Semantic proximity
Select a neighboring publication to make it the new centre.